



UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium)

Press release

Brussels, March 1st, 2005

UCB: CLOSING OF THE SALE OF ITS SURFACE SPECIALTIES DIVISION

Brussels – March 1st, 2005 - UCB confirms today the closing of sale of its Surface Specialties business to Cytec Industries Inc. a global technology leader in specialty chemicals and specialty materials, which occurs in just 5 months after the transaction was announced.

The transaction amount is € 1,415 million of which € 1,190 million in cash and € 225 million in shares of Cytec.

Roch Doliveux, Chairman of the Executive Committee of UCB said: "I would like to pay tribute to everyone involved with "Surface Specialties" for their skill and dedication and to thank them for their contribution to UCB. We wish them well as part of Cytec."

This sale concludes a number of strategic moves initiated with the acquisition of Celltech last May, aimed at transforming UCB into a leading biopharmaceutical company.

* * * * *

About UCB

UCB (www.ucb-group.com) is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specialising in the fields of central nervous system disorders, allergy and respiratory disease, immune and inflammatory disorders and oncology. UCB key products are *Keppra*® (antiepileptic), *Xyzal*® and *Zyrtec*® (antiallergics), *Nootropil*® (cerebral function regulator), *Tussionex*® (antitussive) and *Metadate*® (ADHD*). UCB employs over 8,300 people operating in over 100 countries. UCB is listed on Euronext Brussels, achieved sales of € 3,068 million and a net profit of € 362 million in 2004 including Surface Specialties.

* ADHD: Attention-deficit/hyperactivity disorder

Information:

UCB – Press contacts

Laurence Bataille
Head of Corporate Communications

Tel.: +32 (2) 559 95 88

UCB – Investor Relations contacts

Arnaud Denis
Investor Relations Manager

Tel.: +32 (2) 559 92 64